Skip to main content

Lumora Inks Supply Agreement with Promega

NEW YORK (GenomeWeb News) – UK molecular diagnostics firm Lumora today announced a supply agreement with Promega for use of its luciferase in Lumora's Bioluminescent Assay in Real-Time, or BART, technology.

The deal is the first commercial molecular diagnostic application for Promega's Ultra-Glo luciferase, Lumora said. Its BART technology, a novel reporter system, is used with isothermal nucleic acid amplification technology and causes a sample to light up when a diagnostic test result is positive.

Financial and other terms of the deal were not disclosed.

"Matthew Cook, head of commercial sales for Promega, said that Lumora has "some excellent technologies in the molecular diagnostics space, which combined with Ultra-Glo has the potential to open new markets."

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.